Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 40.00 | |
25 mg | In stock | $ 60.00 | |
50 mg | In stock | $ 74.00 | |
100 mg | In stock | $ 111.00 | |
200 mg | In stock | $ 156.00 | |
500 mg | In stock | $ 258.00 | |
1 g | In stock | $ 383.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU). |
Targets&IC50 | P2Y12:2 nM(Ki) |
Synonyms | AR-C 126532XX, AZD6140 |
Molecular Weight | 522.57 |
Formula | C23H28F2N6O4S |
CAS No. | 274693-27-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (95.68 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ticagrelor 274693-27-5 GPCR/G Protein Metabolism Neuroscience P450 P2Y Receptor AZD-6140 AR-C 126532XX AZD 6140 AZD6140 Inhibitor inhibit inhibitor